Oppenheimer & Co’s Protalix BioTherapeutics PLX Stock Holding History

Oppenheimer & Co’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,500	Closed	-$18K	–	1349
2015 Q3	$18K	Hold	1,500	–	–	﹤0.01%	1332
2015 Q2	$29K	Hold	1,500	–	–	﹤0.01%	1455
2015 Q1	$27K	Sell	1,500 -6,500	-81%	-$127K	﹤0.01%	1463
2014 Q4	$147K	Sell	8,000 -1,700	-18%	-$36.5K	﹤0.01%	1289
2014 Q3	$235K	Buy	9,700 +5,630	+138%	+$162K	0.01%	1178
2014 Q2	$149K	Buy	4,070 +20	+0.5%	+$807	﹤0.01%	1304
2014 Q1	$186K	Buy	4,050 +965	+31%	+$45K	0.01%	1262
2013 Q4	$120K	Buy	+3,085	New	+$130K	﹤0.01%	1302

Other funds holding PLX

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Oppenheimer & Co's PLX Position: Q4 2015 in Review

Oppenheimer & Co sold out of Protalix BioTherapeutics (PLX) in Q4 2015, closing a stake of 1,500 shares — an estimated $18K sold.

Oppenheimer & Co first reported a position in PLX in Q4 2013 and held it in 8 quarters. The position peaked at $235K in Q3 2014. 31 funds tracked by Wall St. Rank hold PLX as of Q4 2015.

Oppenheimer & Co reported no remaining Protalix BioTherapeutics position as of Q4 2015 after selling out during the quarter.
Oppenheimer & Co sold 1,500 Protalix BioTherapeutics shares in Q4 2015, an estimated $18K.
Oppenheimer & Co first reported a position in Protalix BioTherapeutics in Q4 2013 and held it in 8 quarters.
Oppenheimer & Co's Protalix BioTherapeutics position peaked at $235K in Q3 2014.
31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2015.

Based on Oppenheimer & Co's 13F filing for Q4 2015, filed 3 Feb 2016.